The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin
| Autor: | William Biggs, Ian Orozco, Georgia Davis, Katrina J. Ruedy, Roy W. Beck, Janet B. McGill, Anuj Bhargava, Davida F. Kruger, Grazia Aleppo, William H. Polonsky, Quang T Nguyen, Laura A. Young, David Price, John B. Buse, Shichun Bao, Ryan Bailey, Peter Calhoun, Guillermo E. Umpierrez, Rodica Pop-Busui, Athena Philis-Tsimikas, K. Jean Lucas, Thomas W. Martens, Richard M. Bergenstal, Anne L. Peters |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Advanced and Specialized Nursing
Blood glucose monitoring medicine.medical_specialty Randomization endocrine system diseases medicine.diagnostic_test business.industry Continuous glucose monitoring Endocrinology Diabetes and Metabolism Basal insulin nutritional and metabolic diseases Type 2 diabetes medicine.disease Gastroenterology Basal (medicine) Emerging Technologies: Data Systems and Devices Multicenter trial Diabetes mellitus Internal medicine Internal Medicine medicine business |
| Zdroj: | Diabetes Care |
| ISSN: | 1935-5548 0149-5992 |
| DOI: | 10.2337/dc21-1304 |
| Popis: | OBJECTIVE To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin. RESEARCH DESIGN AND METHODS This multicenter trial had an initial randomization to either real-time CGM or blood glucose monitoring (BGM) for 8 months followed by 6 months in which the BGM group continued to use BGM (n = 57) and the CGM group was randomly reassigned either to continue CGM (n = 53) or discontinue CGM with resumption of BGM for glucose monitoring (n = 53). RESULTS In the group that discontinued CGM, mean time in range (TIR) 70–180 mg/dL, which improved from 38% before initiating CGM to 62% after 8 months of CGM, decreased after discontinuing CGM to 50% at 14 months (mean change from 8 to 14 months −12% [95% CI −21% to −3%], P = 0.01). In the group that continued CGM use, little change was found in TIR from 8 to 14 months (baseline 44%, 8 months 56%, 14 months 57%, mean change from 8 to 14 months 1% [95% CI −11% to 12%], P = 0.89). Comparing the two groups at 14 months, the adjusted treatment group difference in mean TIR was −6% (95% CI −16% to 4%, P = 0.20). CONCLUSIONS In adults with type 2 diabetes treated with basal insulin who had been using real-time CGM for 8 months, discontinuing CGM resulted in a loss of about one-half of the initial gain in TIR that had been achieved during CGM use. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|